The Adjuvant Part of Neoantigen Cancer Vaccines: No Clear Winner Has Yet Emerged
- Exploring the use of a cell-based, allogeneic, immune primer for recruitment and activation of cross-presenting DCs
- Harnessing skin-resident memory CD8+ T cells for adaptive immune responses